Absence of Opioid Withdrawal Symptoms in Patients Receiving Methadone and the Protease Inhibitor Lopinavir-Ritonavir

A study was designed to determine the interactions, both clinical and pharmacokinetic, between methadone and lopinavir-ritonavir. Results demonstrated a 36% reduction in the methadone area under the plasma concentration-time curve after the introduction of lopinavir-ritonavir, with no coincident sym...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2002-04, Vol.34 (8), p.1143-1145
Main Authors: Clarke, Susan, Mulcahy, Fiona, Bergin, Colm, Reynolds, Helen, Boyle, Nicola, Barry, Michael, Back, David J.
Format: Article
Language:English
Subjects:
Adult
Analgesics, Opioid - adverse effects
Analgesics, Opioid - blood
Analgesics, Opioid - pharmacokinetics
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiretrovirals
Antiviral agents
Antivirals
Biological and medical sciences
Dosage
Drug Interactions
Enzymes
Female
HIV Infections - drug therapy
HIV Protease Inhibitors - pharmacology
HIV Protease Inhibitors - therapeutic use
HIV/AIDS
Humans
Infectious diseases
Lopinavir
Male
Medical sciences
Methadone
Methadone - adverse effects
Methadone - blood
Methadone - pharmacokinetics
Opioid analgesics
Opioid-Related Disorders - etiology
Pharmacokinetics
Pharmacology. Drug treatments
Pyrimidinones - pharmacology
Pyrimidinones - therapeutic use
Ritonavir - pharmacology
Ritonavir - therapeutic use
RNA, Viral - drug effects
Substance Withdrawal Syndrome - etiology
Withdrawal symptoms
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A study was designed to determine the interactions, both clinical and pharmacokinetic, between methadone and lopinavir-ritonavir. Results demonstrated a 36% reduction in the methadone area under the plasma concentration-time curve after the introduction of lopinavir-ritonavir, with no coincident symptoms of opioid withdrawal and no requirement for methadone dose adjustment.
ISSN:1058-4838
1537-6591
DOI:10.1086/339541